NAFLD vs MASLD (Metabolic Dysfunction–Associated Steatotic Liver Disease)—Why the Need for a Change of Nomenclature? - Takeaways - MDSpire

NAFLD vs MASLD (Metabolic Dysfunction–Associated Steatotic Liver Disease)—Why the Need for a Change of Nomenclature?

  • By

  • Amalia Gastaldelli

  • Philip N Newsome

  • February 19, 2025

  • 0 min

Share

  • 1

    The nomenclature changed from NAFLD to MASLD to address limitations of exclusionary terms and reduce stigma associated with the previous terminology.

  • 2

    MASLD emphasizes the metabolic origin of liver disease, requiring the presence of at least one cardiometabolic risk factor for diagnosis.

  • 3

    The new category MetALD recognizes individuals with liver steatosis and increased alcohol intake, highlighting its impact on disease severity.

  • 4

    The change in nomenclature was supported by a multisociety consensus and aims to improve clarity in diagnosis and treatment of liver diseases.

  • 5

    Current guidelines do not recommend mass screening for MASLD, focusing instead on case-finding in high-risk groups with advanced fibrosis.

Original Source(s)

NAFLD vs MASLD (Metabolic Dysfunction–Associated Steatotic Liver Disease)—Why the Need for a Change of Nomenclature?

  • by Amalia Gastaldelli, Philip N Newsome

  • February 19, 2025

Related Content

A Turning Point in MASH

A billion-dollar acquisition, breakthrough clinical data, and a shifting scientific paradigm are pushing MASH out of the shadows and into a new era of metabolic medicine.

  • by HH Kim

  • January 8, 2026

  • 5 min
Prevalence and Risk Factors of Liver Fibrosis Among People With HIV and Metabolic Dysfunction–Associated Steatotic Liver Disease

Clinical validation of T1ρ mapping for the assessment of hepatic fibrosis in patients with chronic liver disease